Impact of insurance payer and socioeconomic status on type of autologous breast reconstruction Journal Article


Authors: Dinis, J.; Junn, A.; Chouairi, F.; Mercier, M.; Avraham, T.; Matros, E.; Alperovich, M.
Article Title: Impact of insurance payer and socioeconomic status on type of autologous breast reconstruction
Abstract: Introduction: Autologous breast reconstruction has evolved from more morbid procedures that sacrificed the abdominal muscle (the TRAM or transverse rectus abdominus muscle flap) to “perforator” flaps. Commercial insurers recognized the higher technical demand of perforator flaps by creating procedural codes with higher professional fees. This study examined whether procedure code discrepancies between insurance payers disproportionally incentivize perforator flaps among the commercially insured. Methods: Autologous breast reconstructions identified from the National Inpatient Sample (NIS) were subdivided into microvascular perforator (85.74, 85.75, 85.76), microvascular TRAM (85.73), and pedicled TRAM flaps (85.72). Demographics, comorbidities and access to care were compared. A logistic regression comparing microvascular reconstructions only was used to identify predictors for perforator flap reconstruction. Results: A total of 66,968 cases of autologous breast reconstruction were identified. Perforator flaps were more likely among the commercially insured (p < 0.001) and higher insurance quartiles (p < 0.001).When comparing microvascular reconstruction, perforator flaps were 1.72 (p < 0.001) times more likely among the commercially insured. As compared to the lowest income quartile, the fourth quartile had an odds ratio of 1.36 (p < 0.001) for perforator flap reconstruction. Conclusion: The presence of a separate perforator flap billing code among the commercially insured may be exacerbating existing socioeconomic disparities in breast cancer reconstruction. © 2021
Keywords: breast; disparities; autologous; perforator
Journal Title: Surgical Oncology
Volume: 39
ISSN: 0960-7404
Publisher: Elsevier Inc.  
Date Published: 2021-12-01
Start Page: 101661
Language: English
DOI: 10.1016/j.suronc.2021.101661
PROVIDER: scopus
PUBMED: 34534730
PMCID: PMC9069226
DOI/URL:
Notes: Article -- Export Date: 1 October 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Evan Matros
    202 Matros